Literature DB >> 18791417

Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.

Peter Stanwell1, Peter Russell, Jonathan Carter, Selvan Pather, Sebastian Heintze, Carolyn Mountford.   

Abstract

AIM: The purpose of this study was to determine the feasibility of acquiring in vivo proton magnetic resonance spectroscopy of ovarian lesions at a magnetic field strength of 3 Tesla (T). The goal was to provide potentially diagnostic biochemical information that may aid in the characterization of ovarian neoplasms detected during clinical magnetic resonance imaging scanning.
METHODS: Fourteen patients referred to 2 gynecologic oncologic surgeons were examined in a whole-body 3.0 T clinical scanner using an 8-element phased-array surface coil. Single voxel spectroscopy (SVS) was undertaken after identification of lesions on T1-weighted and T2-weighted imaging. SVS was performed using the point resolved spectroscopy (PRESS) localization technique using a echo time (TE) of 135 milliseconds and repetition time (TR) of 2000 milliseconds and with 192 signal averages. Resonance integrals for the prominent signals from choline-containing compounds and creatine (Cr) were studied and presence of other prominent spectroscopic signals reported. Each SVS acquisition was performed in less than 8 minutes. Magnetic resonance spectral findings were correlated with the detailed pathology reports obtained after resection of each tumor.
RESULTS: Pathology revealed 7 patients with malignant surface epithelial-stromal tumors, 3 patients with germ cell tumors, 3 patients with benign serous cystadenomas, and 1 patient with a non-neoplastic endometrioma. Spectroscopic data were acquired from 16 voxels in 14 patients. Resonances attributable to choline-containing compounds and Cr were recorded in all malignant tumors and some of the benign tumors. When detected, a choline/Cr integral ratio of greater than 3 was found to indicate that a tumor was malignant in nature, whereas a choline/Cr integral ratio less than 1.5 was found to indicate that a tumor was benign in nature. There was 1 exception, a 13-cm serous cystadenofibroma, where the choline/Cr integral ratio was 3.13. Several other prominent metabolites were recorded including lactate, lipid, and an as yet unassigned resonance (possibly N-acetylaspartate or sialic acid) at 2.07 ppm.
CONCLUSIONS: Spectroscopy of ovarian masses can be recorded at 3.0 T with acceptable spectral quality and good signal-to-noise ratio. There are stringent technical considerations to be considered in obtaining good spectral quality. Further experience with a larger and more biologically variable range of tumors needs to be undertaken to determine the final clinical utility of this technique, but initial results from this small cohort are promising.

Entities:  

Mesh:

Year:  2008        PMID: 18791417     DOI: 10.1097/RLI.0b013e31817e9104

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  10 in total

1.  Differentiation of benign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T: preliminary study.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2010-10-03       Impact factor: 5.315

Review 2.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

Review 3.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

4.  Proton MR spectroscopy and the detection of malignancy in ovarian masses.

Authors:  Sahar Mahmoud Mansour; Mohammed Mohammed Mohammed Gomma; Peter Nashaat Shafik
Journal:  Br J Radiol       Date:  2019-07-18       Impact factor: 3.039

5.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy.

Authors:  D Ben Sellem; K Elbayed; A Neuville; F-M Moussallieh; G Lang-Averous; M Piotto; J-P Bellocq; I J Namer
Journal:  J Oncol       Date:  2011-04-26       Impact factor: 4.375

Review 6.  In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.

Authors:  Rossella Canese; Delia Mezzanzanica; Marina Bagnoli; Stefano Indraccolo; Silvana Canevari; Franca Podo; Egidio Iorio
Journal:  Front Oncol       Date:  2016-06-28       Impact factor: 6.244

Review 7.  Ovarian Cancer Targeted Theranostics.

Authors:  Sridhar Nimmagadda; Marie-France Penet
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

8.  PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model.

Authors:  Jiefu Jin; Ishwarya Sivakumar; Yelena Mironchik; Balaji Krishnamachary; Flonné Wildes; James D Barnett; Chien-Fu Hung; Sridhar Nimmagadda; Hisataka Kobayashi; Zaver M Bhujwalla; Marie-France Penet
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.575

9.  Two-dimensional correlated spectroscopy distinguishes clear cell renal cell carcinoma from other kidney neoplasms and non-cancer kidney.

Authors:  Sharon J Del Vecchio; Aaron J Urquhart; Xin Dong; Robert J Ellis; Keng Lim Ng; Hemamali Samaratunga; Sonja Gustafson; Graham J Galloway; Glenda C Gobe; Simon Wood; Carolyn E Mountford
Journal:  Transl Androl Urol       Date:  2022-07

10.  Effects of contrast agent and outer volume saturation bands on water suppression and shimming of hepatic single-volume proton MR spectroscopy at 3.0T.

Authors:  Li Xu; Yan Huang; Xian Liu; Bo Liu
Journal:  ScientificWorldJournal       Date:  2012-11-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.